A randomized trial of icosapent ethyl in ambulatory patients with COVID-19 - Centre de recherche Saint-Antoine - UMR S938 Accéder directement au contenu
Article Dans Une Revue iScience Année : 2021

A randomized trial of icosapent ethyl in ambulatory patients with COVID-19

Deepak L Bhatt
  • Fonction : Auteur
  • PersonId : 1110761
Lixia Jiao
  • Fonction : Auteur
Robert Wang
  • Fonction : Auteur
Rebecca A Juliano
  • Fonction : Auteur
Abdullahi A Berih
  • Fonction : Auteur
Andrew Leung
  • Fonction : Auteur
Idelta Coelho
  • Fonction : Auteur
Arthur Kushner
  • Fonction : Auteur

Résumé

The coronavirus disease 2019 (COVID-19) pandemic remains a source of considerable morbidity and mortality throughout the world. Therapeutic options to reduce symptoms, inflammatory response, or disease progression are limited. This randomized open-label trial enrolled 100 ambulatory patients with symptomatic COVID-19 in Toronto, Canada. Results indicate that icosapent ethyl (8 g daily for 3 days followed by 4 g daily for 11 days) significantly reduced high-sensitivity C-reactive protein (hs-CRP) and improved symptomatology compared with patients assigned to usual care. Specifically, the primary biomarker endpoint, change in hs-CRP, was significantly reduced by 25% among treated patients (−0.5 mg/L, interquartile range [IQR] [−6.9,0.4], within-group p = 0.011). Conversely, a non-significant 5.6% reduction was observed among usual care patients (−0.1 mg/L, IQR [−3.2,1.7], within-group p = 0.51). An unadjusted between-group primary biomarker analysis was non-significant (p = 0.082). Overall, this report provides evidence of an early anti-inflammatory effect of icosapent ethyl in a modest sample, including an initial well-tolerated loading dose, in symptomatic outpatients with COVID-19. ClinicalTrials.gov Identifier: NCT04412018.

Mots clés

Fichier principal
Vignette du fichier
PIIS2589004221010087.pdf (1.96 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03350436 , version 1 (21-09-2021)

Identifiants

Citer

Andrew Kosmopoulos, Deepak L Bhatt, Gus Meglis, Raj Verma, Yi Pan, et al.. A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. iScience, 2021, 24 (9), pp.103040. ⟨10.1016/j.isci.2021.103040⟩. ⟨hal-03350436⟩
33 Consultations
47 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More